Home/Pipeline/Pyrotinib

Pyrotinib

HER2-positive breast cancer

ApprovedCommercial

Key Facts

Indication
HER2-positive breast cancer
Phase
Approved
Status
Commercial
Company

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd. is a leading Chinese pharmaceutical company founded in 1970, headquartered in Lianyungang, Jiangsu Province. The company has evolved from producing generic drugs to becoming a major innovator in oncology, with particular strength in developing novel cancer treatments, anesthesia drugs, and medical imaging contrast agents. Hengrui has established itself as one of China's most valuable pharmaceutical companies with significant R&D investments and an expanding global footprint.

View full company profile